title: [CYP 2D6 activity profile among patients with depression].
abstract: OBJECTIVE
  The aim of this work was to establish the profile of CYP 2D6 activity among patients with depressive disorders, and compare it with the literature data on this activity among healthy volunteers, recruited from the Polish population.
  
  
  METHODS
  The debrisoquine test was used to determine CYP 2D6 activity. Debrisoquine metabolic ratio (MR) was determined with the use of high performance liquid chromatography with spectrophotometric detection. Our results were compared with the results obtained with the use of an analogous method in the study performed at the Institute of Cardiology in Warsaw on 154 healthy controls.
  
  
  RESULTS
  The percentage of "ultra-fast metabolizers" was 1.03% in the group of patients with depression, and 1.3% in the group of healthy volunteers. The percentages of the "slow metabolizers" in both groups were 5.1% and 5.6% respectively. Also, the percentages of persons considered to be at an increased risk of undesirable side effects from drugs metabolized by CYP 2D6, i.e. persons with debrisoquine metabolic ratio values above 4 were nearly identical in both groups (11.3 and 11.6%).
  
  
  CONCLUSIONS
  The results showed that CYP 2D6 activity profiles were practically identical in both groups. This indicates that there is no relationship between CYP 2D6 gene expression, as measured by the debrisoquine test, and affective disorders morbidity.
authors.affiliation: Zakładu Neurochemii IPiN w Warszawie.
authors.forename: Andrzej
authors.initials: A
authors.lastname: Bidziński
authors.forename: Iwona
authors.initials: I
authors.lastname: Koszewska
authors.forename: Danuta
authors.initials: D
authors.lastname: Turzyńska
authors.forename: Antoni
authors.initials: A
authors.lastname: Kalinowski
authors.forename: Lukasz
authors.initials: L
authors.lastname: Swiecicki
authors.forename: Marek
authors.initials: M
authors.lastname: Dabrowski
authors.forename: Jarosław
authors.initials: J
authors.lastname: Torbiński
authors.forename: Elzbieta
authors.initials: E
authors.lastname: Burna-Drazkowic
authors.forename: Sławomir
authors.initials: S
authors.lastname: Fornal
authors.forename: Dorota
authors.initials: D
authors.lastname: Gradzka
authors.forename: Magdalena
authors.initials: M
authors.lastname: Namysłowska
authors.forename: Stanisław
authors.initials: S
authors.lastname: Puzyński
authors.forename: Adam
authors.initials: A
authors.lastname: Płaźnik
mesh_terms: D018663:Adrenergic Agents / Q000378:metabolism*; D000328:Adult; D000368:Aged; D016022:Case-Control Studies; D002851:Chromatography, High Pressure Liquid; D019389:Cytochrome P-450 CYP2D6 / Q000378:metabolism*; D003647:Debrisoquin / Q000378:metabolism*; D003866:Depressive Disorder / Q000201:enzymology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D013056:Spectrophotometry, Ultraviolet; D018709:Statistics, Nonparametric; D013997:Time Factors
chemical_list: D018663:Adrenergic Agents; D019389:Cytochrome P-450 CYP2D6; D003647:Debrisoquin